Hyperbilirubinemia Clinical Trial
Official title:
Comparison of Light-emitting Diodes (LED) Phototherapy Versus Fluorescent Lamps Phototherapy for Treatment of Hyperbilirubinemia in Term Newborn
Phototherapy is almost (beside exchange transfusion) the unique treatment for hyperbilirubinemia of the newborn. Its efficacy to decrease bilirubin level (because the light interacts with bilirubin at the skin level to transform it in water soluble products eliminated in urine and stools without liver metabolism) relies on the irradiance dispensed at the skin level by the device (in the 430-490nm range) and on the exposed surface of the baby. In the past years, technology of phototherapy devices moved from fluorescent lamps to LED, improving the amount of light energy emitted but on a smaller surface. The purpose of the study is to compare the efficacy of three ramps of phototherapy, one equipped with fluorescent tubes and two with LED (in a different technological settings) in the treatment of term (35 GW or more) healthy newborn suffering hyperbilirubinemia after 2days of life.
Term and healthy newborns on maternity wards in SAINT-ANTOINE hospital are checked everyday for jaundice with bilirubinometer JM-103®. If indicated (nomogram included in patient charts), a plasmatic bilirubin level is performed. If the baby is two days old or more with a bilirubin level indicating standard phototherapy (by opposition to intensive phototherapy), the parents are informed of the research protocol and after obtention of parental consent, the baby is included. The newborn is admitted in the neonatology unit and randomised in one of the three phototherapy devices group. Plasmatic bilirubin levels are checked at 6,12 and 24 and 48 hours of phototherapy. At 12 hours of phototherapy, a biological checking is performed to address the etiology of the jaundice. The next plasmatic bilirubin level is performed at 72h after inclusion. During phototherapy treatment the baby is continuously monitored. Phototherapy is stopped when bilirubin level is below 200µmol/l. If the bilirubin level is increasing under one of this ramps or does not decrease at H24, the baby will be immediately move on intensive phototherapy and participation at the research protocol interrupted. Twenty four hours after the end of phototherapy treatment, plasmatic bilirubin level is checked to confirm the end of jaundice and statement is made for jaundice origin. The total duration of participation of a baby at this study is 72 hours. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00383318 -
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia
|
N/A | |
Completed |
NCT00360204 -
Improving Health Outcomes for New Mothers and Babies
|
Phase 3 | |
Completed |
NCT00115544 -
Safety and Pharmacology of Stanate
|
Phase 2 | |
Completed |
NCT01622699 -
Implementation of a Transcutaneous Bilirubinometer
|
N/A | |
Terminated |
NCT00741117 -
Conjugated Hyperbilirubinemia and Pulse Oximetry
|
N/A | |
Completed |
NCT00288600 -
Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
|
Phase 4 | |
Completed |
NCT02774434 -
Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age
|
N/A | |
Completed |
NCT01550627 -
Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy
|
Phase 0 | |
Completed |
NCT00653874 -
Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates
|
Phase 3 | |
Recruiting |
NCT03564678 -
Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT04897113 -
Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old
|
N/A | |
Recruiting |
NCT01944696 -
Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?
|
N/A | |
Completed |
NCT00635375 -
Comparative Study of Phototherapy for Hyperbilirubinemia
|
N/A | |
Completed |
NCT03195998 -
Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants
|
||
Terminated |
NCT02685189 -
Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)
|
||
Completed |
NCT02446951 -
Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department
|
||
Completed |
NCT04271098 -
The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries
|
||
Completed |
NCT02691156 -
Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
|
||
Completed |
NCT00004381 -
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia
|
Phase 2 | |
Completed |
NCT00004382 -
Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns
|
Phase 2 |